Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 24: New Insights from CLEAR OUTCOMES
Author(s): Marc P Bonaca Added: 1 year ago
AHA Conference 2024 - New insights from the CLEAR OUTCOMES trial investigating bempedoic acid (Esperion Therapeutics Inc.) in statin-intolerant patients with peripheral arterial disease (PAD).Dr Marc Bonaca (University of Colorado School of Medicine, Colorado, US) joins us onsite at AHA Conference to discuss new insights from CLEAR OUTCOMES (NCT02993406).CLEAR OUTCOMES is a double-blind,… View more

Vascular Disease and Surgery

Prevention & Chronic Conditions
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions
Atorvastatin and Ezetimibe in Patients with Acute Coronary Syndrome
Author(s): Mohammed Sallam , Hossameldin Hassan , Derek Connolly , et al Added: 1 year ago

Prevention & Chronic Conditions

MI/ACS
30th Annual Meeting of the ISCP
Author(s): María Iglesias Alonso , Jose Manuel Iglesias Sanmartin Added: 1 month ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
30th Annual Meeting of the ISCP
Author(s): Jordi Cahís , Pablo Carrión-Montaner , Jordi Sans , et al Added: 1 month ago

Prevention & Chronic Conditions

Heart Failure
ESC 25: The NEWTON-CABG CardioLink-5 Study
Author(s): Subodh Verma Added: 8 months ago
ESC Congress 2025 - NEWTON-CABG finds evolocumab with regular statin therapy did not improve vein graft patency after coronary artery bypass graft (CABG) surgery in the short-term.Dr Subodh Verma and Dr Lawrence Leiter (University of Toronto, Toronto, CA) join us to discuss findings from NEWTON-CABG CardioLink-5 (NCT03900026). The investigator-initiated multicenter, randomised, placebo-controlled… View more

Intervention
Frailty and Cardiovascular Risk
Author(s): Nicholas R Evans , Shiv Bhakta , Claudia Zeicu , et al Added: 2 weeks ago

Prevention & Chronic Conditions

Cardiovascular Kidney Metabolic
Targeted Lipid Control in Very-high-risk Indian Patients: Expert Insights
Author(s): Kausik Ray , Upendra Kaul , Srinivasa Rao , et al Added: 5 months ago

Guidelines & Statements
Ez-PAVE: Lower LDL-C Target Reduces CV Events
Added: 1 month ago Source:  Radcliffe CVRM
Recent US guidelines have controversially recommended lowering the low-density lipoprotein cholesterol (LDL-C) target to <55 mg/dL for patients with established atherosclerotic cardiovascular disease (ASCVD).¹˒² The Ez-PAVE trial is the first randomised study to directly compare this intensive target with a conventional target of <70 mg/dL. The findings were published in The New England… View more

Cardiovascular Kidney Metabolic

Demographic